首页|尿肝型脂肪酸结合蛋白(L-FABP)对慢加急性肝衰竭短期预后的预测价值

尿肝型脂肪酸结合蛋白(L-FABP)对慢加急性肝衰竭短期预后的预测价值

扫码查看
目的 探讨肝型脂肪酸结合蛋白(L-FABP)对慢加急性肝衰竭(ACLF)患者严重程度及短期预后的预测价值.方法 研究对象149例来自于一个评估ACLF患者血小板功能的前瞻性、多中心队列,根据入院28天预后分为生存组(n=97)与死亡组(n=52).分析患者的性别、年龄、病因以及入院后24 h内的血常规、生化指标、器官衰竭情况并检测尿液及血液中L-FABP水平.正态分布的计量资料2组间比较使用成组t检验;非正态资料分布的计量资料2组间比较采用Mann-Whitney U检验;计数资料2组间比较采用χ2检验.Spearman相关性检验评估尿L-FABP与肝衰竭相关指标的相关性.绘制受试者工作特征曲线(ROC曲线)评价CLIF-OFs、MELD评分和尿L-FABP对于ACLF患者短期预后的预测价值;通过Kaplan-Meier分析尿L-FABP高水平组与低水平组患者短期死亡情况;采用Cox风险比例模型分析各因素对ACLF短期预后的影响.结果 两组患者在白细胞计数、血清TBil、INR、CLIF-OFs、MELD评分和尿L-FABP水平;脑衰竭、肝衰竭、凝血衰竭、肾脏衰竭、呼吸衰竭的比例方面差异均有统计学意义(P值均<0.05).相关性分析结果显示,尿L-FABP与血清TBil呈显著正相关(r=0.225,P=0.006).尿L-FABP水平预测28天预后的ROC曲线下面积(AUC)为0.804(95%CI:0.729~0.865,P<0.001),截断值为4.779 μg/dL(敏感度为73.08%,特异度为73.91%,约登指数为0.469 9).Kaplan-Meier生存分析发现,相比于尿L-FABP低水平组(尿L-FABP≤4.779 μg/dL),尿L-FABP高水平组(尿L-FABP>4.779 μg/dL)28天生存率显著降低(P<0.001).Cox风险比例模型分析发现,血清TBil(HR=1.003,95%CI:1.001~1.004)、CLIF-OFs(HR=2.283,95%CI:1.814~2.873)和高尿L-FABP水平(HR=4.568,95%CI:2.424~8.608)为ACLF短期预后的独立危险因素(P值均<0.05).结论 高尿L-FABP水平可作为ACLF短期预后的临床预测指标,需扩大样本量进一步验证其预测价值.
Value of urinary liver fatty acid-binding protein in predicting the short-term prognosis of patients with acute-on-chronic liver failure
Objective To investigate the value of liver fatty acid-binding protein(L-FABP)in predicting the severity and short-term prognosis of patients with acute-on-chronic liver failure(ACLF).Methods A total of 149 patients with ACLF were selected from a prospective multicenter cohort assessing the platelet function of ACLF patients,and according to the 28-day prognosis after admission,they were divided into survival group with 97 patients and death group with 52 patients.The patients were analyzed in terms of sex,age,etiology,and blood routine,biochemical parameters,and organ failure status within 24 hours after admission,and the level of L-FABP in urine and blood was measured.The independent-samples t test was used for comparison of normally distributed continuous data between two groups,and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups;the chi-square test was used for comparison of categorical data between two groups.The Spearman test was used to evaluate the correlation between urinary L-FABP and indicators for liver failure.The receiver operating characteristic(ROC)curve was plotted to assess the value of CLIF-OFs,MELD score,and urinary L-FABP in predicting the short-term prognosis of ACLF patients;the Kaplan-Meier analysis was used to evaluate short-term mortality in the high urinary L-FABP group and the low urinary L-FABP group;the Cox proportional hazards model was used to investigate the association of each factor with the short-term prognosis of ACLF.Results There were significant differences between the two groups in white blood cell count,serum total bilirubin(TBil),international normalized ratio,CLIF-OFs,MELD score,urinary L-FABP level,and the proportion of patients with cerebral failure,liver failure,coagulation failure,renal failure,or respiratory failure(all P<0.05).The Spearman correlation analysis showed that urinary L-FABP was significantly positively correlated with serum TBil(r=0.225,P=0.006).Urinary L-FABP level had an area under the ROC curve of 0.804(95%confidence interval[CI]:0.729-0.865,P<0.001)and a cut-off value of 4.779 μg/dL,with a sensitivity of 73.08%,a specificity of 73.91%,and a Youden index of 0.469 9.The Kaplan-Meier survival analysis showed that compared with the low urinary L-FABP group(urinary L-FABP≤4.779 μg/dL),the high urinary L-FABP group(urinary L-FABP>4.779 μg/dL)had a significantly lower 28-day survival rate(P<0.001).The Cox proportional hazards model analysis showed that serum TBil(hazard ratio[HR]=1.003,95%CI:1.001-1.004,P<0.05),CLIF-OFs(HR=2.283,95%CI:1.814-2.873,P<0.05),and high urinary L-FABP level(HR=4.568,95%CI:2.424-8.608,P<0.05)were independent risk factors for the short-term prognosis of ACLF.Conclusion High urinary L-FABP level can be used as a clinical indicator for predicting the short-term prognosis of ACLF,and further studies with larger sample sizes are needed to evaluate its predictive value.

Acute-On-Chronic Liver FailureLiver CirrhosisFatty Acid-Binding ProteinsPrognosis

吴华兰、洪畅泽、蒋秀华、陈金军

展开 >

南方医科大学南方医院感染内科,广州 510515

南方医科大学南方医院增城分院肝病中心,广州 511300

器官衰竭防治国家重点实验室,广州 510515

广东省病毒性肝炎研究重点实验室,广州 510515

华南传染病防治教育部重点实验室,广州 510515

展开 >

慢加急性肝功能衰竭 肝硬化 脂肪酸结合蛋白质类 预后

国家重点研发专项国家自然科学基金国家自然科学基金国家科技部重大专项广东省珠江人才计划南方医院临床研究专项南方医院临床研究专项南方医科大学临床启动计划南方医院院长基金广东省重点领域研发计划

2022YFC230480082370614820706502018ZX107232032017BT01S1312018CR0372020CR026LC2019ZD0062019Z0032019B020227004

2024

临床肝胆病杂志
吉林大学

临床肝胆病杂志

CSTPCD北大核心
影响因子:1.428
ISSN:1001-5256
年,卷(期):2024.40(8)